Login to Your Account

The Liver Meeting 2011

Transgene Struts Good Data, Seeks Partner for HCV Vaccine

By Cormac Sheridan
BioWorld Today Correspondent

Tuesday, November 8, 2011

Transgene SA became the latest contender to jump on board the interferon-free bandwagon in hepatitis C virus (HCV) therapy, as it unveiled interim data from a 153-patient Phase II trial of its therapeutic vaccine TG-4040, which indicated that the vaccine, when administered in combination with the standard therapy of pegylated interferon alpha plus ribavirin (PEG/Riba) was twice as effective in eliciting a complete early virologic response (cEVR) as standard therapy alone.

Transgene is now seeking a series of nonexclusive partnerships to enable it to test TG-4040 in a variety of inte

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription